Novel strategy for a bispecific antibody: induction of dual target internalization and degradation (Q50882714)

24 March 2018

title

Novel strategy for a bispecific antibody: induction of dual target internalization and degradation (English)

1 reference

24 March 2018

author name string

J M Lee

1

1 reference

24 March 2018

S H Lee

2

1 reference

24 March 2018

J-W Hwang

3

1 reference

24 March 2018

S J Oh

4

1 reference

24 March 2018

B Kim

5

1 reference

24 March 2018

S Jung

6

1 reference

24 March 2018

S-H Shim

7

1 reference

24 March 2018

P W Lin

8

1 reference

24 March 2018

S B Lee

9

1 reference

24 March 2018

M-Y Cho

10

1 reference

24 March 2018

Y J Koh

11

1 reference

24 March 2018

S Y Kim

12

1 reference

24 March 2018

S Ahn

13

1 reference

24 March 2018

J Lee

14

1 reference

24 March 2018

K-M Kim

15

1 reference

24 March 2018

K H Cheong

16

1 reference

24 March 2018

J Choi

17

1 reference

24 March 2018

K-A Kim

18

1 reference

24 March 2018

language of work or name

English

0 references

publication date

8 February 2016

1 reference

24 March 2018

published in

Oncogene

1 reference

24 March 2018

volume

35

1 reference

24 March 2018

issue

34

1 reference

24 March 2018

page(s)

4437-4446

1 reference

24 March 2018

Cell signaling by receptor tyrosine kinases

cites work

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Therapeutic targeting of the epidermal growth factor receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

c-MET as a potential therapeutic target and biomarker in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

HGF-independent potentiation of EGFR action by c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Epidermal growth factor receptor: pathway, therapies, and pipeline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

USP8 modulates ubiquitination of LRIG1 for Met degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Targeting HSP90 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

The therapeutic target Hsp90 and cancer hallmarks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Patient-derived cell models as preclinical tools for genome-directed targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Targeted therapies in development for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Antibody therapeutics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Therapeutic potential of RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Current prospects for RNA interference-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Prospects of RNA interference therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Monoclonal antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2015.514

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26853467

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26853467

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2015.514

1 reference

24 March 2018

1 reference

24 March 2018